An Update on Surveillance in Ulcerative Colitis

Inflammatory Bowel Disease (S Hanauer, Section Editor)
  • 195 Downloads
Part of the following topical collections:
  1. Topical Collection on Inflammatory Bowel Disease

Abstract

Purpose of Review

Patients with long-standing ulcerative colitis have an increased risk for the development of colorectal cancer (CRC). Colitis-related dysplasia appears to confer the greatest risk. Colonoscopic surveillance to detect dysplasia has been advocated by gastrointestinal societies. The aim of surveillance is the reduction of mortality and morbidity of CRC through detection and resection of dysplasia or detecting CRC at an earlier and potentially curable stage. Traditional surveillance has relied on mucosal assessment with targeted biopsy of visible lesions and random biopsy sampling on the premise that dysplasia was not visible at endoscopy. Advances in optical technology permitting increased detection of dysplasia and evidence that most dysplasia is visible has had practice-changing implications.

Recent Findings

Emerging evidence favours chromoendoscopy (CE) for dysplasia detection and is gaining wider acceptance through recent international (International Consensus Statement on Surveillance and Management of Dysplasia in Inflammatory Bowel Disease (SCENIC)) recommendations and endorsed by many gastrointestinal societies. Adoption of CE as the gold standard of surveillance has been met with by scepticism, from conflicting data, operational barriers and the need to understand the true impact of increasingly higher dysplasia detection on overall CRC mortality.

Summary

Valid debate notwithstanding, implementation of a risk stratification protocol that includes CE is an effective approach allowing earlier detection of dysplasia and colorectal neoplasia, determination of surveillance intervals with appropriate allocation of resources and limiting morbidity from CRC and colonoscopy itself. Further prospective data should define the true and long-term impact of dysplasia detection with modern techniques.

Keywords

Dysplasia Ulcerative colitis Surveillance Colorectal cancer 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;373(195).  https://doi.org/10.1056/NEJMc1505689.
  2. 2.
    Farraye FA, Odze RD, Eaden J, et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746–74. 774 e1–4; quiz e12–3CrossRefPubMedGoogle Scholar
  3. 3.
    Itzkowitz SH, Present DH, Crohn's, et al. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11(3):314–21.  https://doi.org/10.1097/01.MIB.0000160811.76729.d5.CrossRefPubMedGoogle Scholar
  4. 4.
    •• American Society for Gastrointestinal Endoscopy Standards of Practice C, Shergill AK, Lightdale JR, et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015;81:1101–21 e1–13. A comprehensive evidence based update from the ASGE with useful algorithms for managing dysplasia in IBD patients CrossRefGoogle Scholar
  5. 5.
    Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649–70.CrossRefPubMedGoogle Scholar
  6. 6.
    Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607.CrossRefPubMedGoogle Scholar
  7. 7.
    Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of G. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–23; quiz 524.  https://doi.org/10.1038/ajg.2009.727.CrossRefPubMedGoogle Scholar
  8. 8.
    Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5):666–89.  https://doi.org/10.1136/gut.2009.179804.CrossRefPubMedGoogle Scholar
  10. 10.
    Colman RJ, Rubin DT. Histological inflammation increases the risk of colorectal neoplasia in ulcerative colitis: a systematic review. Intest Res. 2016;14(3):202–10.  https://doi.org/10.5217/ir.2016.14.3.202.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982–1018.CrossRefPubMedGoogle Scholar
  12. 12.
    Rutter MD, Riddell RH. Colorectal dysplasia in inflammatory bowel disease: a clinicopathologic perspective. Clin Gastroenterol Hepatol. 2014;12(3):359–67.  https://doi.org/10.1016/j.cgh.2013.05.033.CrossRefPubMedGoogle Scholar
  13. 13.
    Rutter MD, Saunders BP, Wilkinson KH, Kamm MA, Williams CB, Forbes A. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc. 2004;60(3):334–9.  https://doi.org/10.1016/S0016-5107(04)01710-9.CrossRefPubMedGoogle Scholar
  14. 14.
    Rubin DT, Rothe JA, Hetzel JT, Cohen RD, Hanauer SB. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007;65(7):998–1004.  https://doi.org/10.1016/j.gie.2006.09.025.CrossRefPubMedGoogle Scholar
  15. 15.
    Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18(Suppl 2):1–5.  https://doi.org/10.1046/j.1365-2036.18.s2.2.x.CrossRefPubMedGoogle Scholar
  16. 16.
    Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–35.  https://doi.org/10.1136/gut.48.4.526.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Choi CH, Rutter MD, Askari A, et al. Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. Am J Gastroenterol. 2015;110(7):1022–34.  https://doi.org/10.1038/ajg.2015.65.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Jess T, Simonsen J, Jorgensen KT, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143:375–81. e1; quiz e13–4CrossRefPubMedGoogle Scholar
  19. 19.
    Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228–33.CrossRefPubMedGoogle Scholar
  20. 20.
    Floren CH, Benoni C, Willen R. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol. 1987;22(4):459–62.  https://doi.org/10.3109/00365528708991491.CrossRefPubMedGoogle Scholar
  21. 21.
    Meucci G, Vecchi M, Astegiano M, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol. 2000;95:469–73.CrossRefPubMedGoogle Scholar
  22. 22.
    Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56(1):48–54.  https://doi.org/10.1067/mge.2002.125367.CrossRefPubMedGoogle Scholar
  23. 23.
    Saxena AP, Limdi JK, Farraye FA. Zeroing in on endoscopic and histologic mucosal healing to reduce the risk of colorectal neoplasia in inflammatory bowel disease. Gastrointest Endosc. 2017;86(6):1012–4.  https://doi.org/10.1016/j.gie.2017.08.029.CrossRefPubMedGoogle Scholar
  24. 24.
    Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013;11:1601–8 e1–4.CrossRefPubMedGoogle Scholar
  25. 25.
    •• Flores BM, O'Connor A, Moss AC. Impact of mucosal inflammation on risk of colorectal neoplasia in patients with ulcerative colitis: a systematic review and meta-analysis. Gastrointest Endosc 2017. A recent meta-analysis assessing the impact of histological inflammation on colorectal cancer risk in IBD raising further debate on whether mucosal healing alone is sufficient to reduce colitis-associated colorectal cancer risk. Google Scholar
  26. 26.
    •• Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. 2015;148:639–651 e28. An international consensus with practice-changing implications to dysplasia surveillance and endorsed by most GI societies. CrossRefPubMedGoogle Scholar
  27. 27.
    Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett. 2014;345(2):235–41.  https://doi.org/10.1016/j.canlet.2013.07.032.CrossRefPubMedGoogle Scholar
  28. 28.
    Chiba T, Marusawa H, Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology. 2012;143(3):550–63.  https://doi.org/10.1053/j.gastro.2012.07.009.CrossRefPubMedGoogle Scholar
  29. 29.
    Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003;3(4):276–85.  https://doi.org/10.1038/nrc1046.CrossRefPubMedGoogle Scholar
  30. 30.
    Redston MS, Papadopoulos N, Caldas C, et al. Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology. 1995;108:383–92.CrossRefPubMedGoogle Scholar
  31. 31.
    Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology. 1992;103(5):1611–20.  https://doi.org/10.1016/0016-5085(92)91185-7.CrossRefPubMedGoogle Scholar
  32. 32.
    Burmer GC, Rabinovitch PS, Haggitt RC, Crispin d, Brentnall TA, Kolli VR, et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology. 1992;103(5):1602–10.  https://doi.org/10.1016/0016-5085(92)91184-6.CrossRefPubMedGoogle Scholar
  33. 33.
    Cartwright CA, Coad CA, Egbert BM. Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis. J Clin Invest. 1994;93(2):509–15.  https://doi.org/10.1172/JCI117000.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Kisiel JB, Konijeti GG, Piscitello AJ, Chandra T, Goss TF, Ahlquist d, et al. Stool DNA analysis is cost effective for colorectal cancer surveillance in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14(12):1778–87.  https://doi.org/10.1016/j.cgh.2016.07.018.PubMedCentralCrossRefPubMedGoogle Scholar
  35. 35.
    Kanthan R, Senger JL, Kanthan SC. Fecal molecular markers for colorectal cancer screening. Gastroenterol Res Pract. 2012;2012:184343.CrossRefPubMedGoogle Scholar
  36. 36.
    Kaminski MF, Hassan C, Bisschops R, et al. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2014;46(5):435–49.  https://doi.org/10.1055/s-0034-1365348.CrossRefPubMedGoogle Scholar
  37. 37.
    The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003;58:S3–43, 6, DOI:  https://doi.org/10.1016/S0016-5107(03)02159-X.
  38. 38.
    Siegel CA, Schwartz LM, Woloshin S, Cole EB, Rubin DT, Vay T, et al. When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Dis. 2010;16(10):1658–62.  https://doi.org/10.1002/ibd.21233.PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Watanabe T, Ajioka Y, Mitsuyama K, et al. Comparison of targeted vs random biopsies for surveillance of ulcerative colitis-associated colorectal cancer. Gastroenterology. 2016;151:1122–30.CrossRefPubMedGoogle Scholar
  40. 40.
    Wang YR, Cangemi JR, Loftus EV Jr, Picco MF. Rate of early/missed colorectal cancers after colonoscopy in older patients with or without inflammatory bowel disease in the United States. Am J Gastroenterol. 2013;108(3):444–9.  https://doi.org/10.1038/ajg.2012.429.CrossRefPubMedGoogle Scholar
  41. 41.
    Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003;124:880–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Matsumoto T, Nakamura S, Jo Y, Yao T, Iida M. Chromoscopy might improve diagnostic accuracy in cancer surveillance for ulcerative colitis. Am J Gastroenterol. 2003;98(8):1827–33.  https://doi.org/10.1111/j.1572-0241.2003.07580.x.CrossRefPubMedGoogle Scholar
  43. 43.
    Hurlstone DP, McAlindon ME, Sanders DS, Keogh R, Lobo AJ, Cross SS. Further validation of high-magnification chromoscopic-colonoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2004;126(1):376–8.  https://doi.org/10.1053/j.gastro.2003.05.021.CrossRefPubMedGoogle Scholar
  44. 44.
    Subramanian V, Mannath J, Ragunath K, et al. Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:304–12.CrossRefPubMedGoogle Scholar
  45. 45.
    Konijeti GG, Shrime MG, Ananthakrishnan AN, Chan AT. Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients with ulcerative colitis. Gastrointest Endosc. 2014;79(3):455–65.  https://doi.org/10.1016/j.gie.2013.10.026.CrossRefPubMedGoogle Scholar
  46. 46.
    •• Iannone A, Ruospo M, Wong G, et al. Chromoendoscopy for surveillance in ulcerative colitis and Crohn’s disease: a systematic review of randomized trials. Clin Gastroenterol Hepatol 2017;(11):1684-1697. An important meta-analysis summarising the evidence for chromoendoscopy for dysplasia surveillance in IBD.Google Scholar
  47. 47.
    •• Soetikno R, Sanduleanu S, Kaltenbach T. An atlas of the nonpolypoid colorectal neoplasms in inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2014;24(3):483–520. An essential resource for endoscopists for lesion recognition and chromoendoscopy.  https://doi.org/10.1016/j.giec.2014.04.003.CrossRefPubMedGoogle Scholar
  48. 48.
    Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB, Talbot IC. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut. 2004;53(2):256–60.  https://doi.org/10.1136/gut.2003.016386.PubMedCentralCrossRefPubMedGoogle Scholar
  49. 49.
    Soetikno R, Subramanian V, Kaltenbach T, et al. The detection of nonpolypoid (flat and depressed) colorectal neoplasms in patients with inflammatory bowel disease. Gastroenterology. 2013;144:1349–52. 1352 e1–6CrossRefPubMedGoogle Scholar
  50. 50.
    Moussata D, Allez M, Cazals-Hatem D, et al. Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy? Gut 2017.Google Scholar
  51. 51.
    Navaneethan U, Jegadeesan R, Gutierrez NG, et al. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance. J Crohns Colitis. 2013;7:e684–91.CrossRefPubMedGoogle Scholar
  52. 52.
    van den Broek FJ, Stokkers PC, Reitsma JB, et al. Random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis: low yield and absence of clinical consequences. Am J Gastroenterol. 2014;109(5):715–22.  https://doi.org/10.1038/ajg.2011.93.CrossRefPubMedGoogle Scholar
  53. 53.
    Hurlstone DP, Sanders DS, Atkinson R, Hunter MD, McAlindon ME, Lobo AJ, et al. Endoscopic mucosal resection for flat neoplasia in chronic ulcerative colitis: can we change the endoscopic management paradigm? Gut. 2007;56(6):838–46.  https://doi.org/10.1136/gut.2006.106294.CrossRefPubMedGoogle Scholar
  54. 54.
    Higgins PD. Miles to go on the SCENIC route: should chromoendoscopy become the standard of care in IBD surveillance? Am J Gastroenterol. 2015;110:1035–7.CrossRefPubMedGoogle Scholar
  55. 55.
    Kiesslich R, Goetz M, Lammersdorf K, et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology. 2007;132:874–82.CrossRefPubMedGoogle Scholar
  56. 56.
    Wu L, Li P, Wu J, Cao Y, Gao F. The diagnostic accuracy of chromoendoscopy for dysplasia in ulcerative colitis: meta-analysis of six randomized controlled trials. Color Dis. 2012;14(4):416–20.  https://doi.org/10.1111/j.1463-1318.2010.02505.x.CrossRefGoogle Scholar
  57. 57.
    Marion JF, Sands BE. The SCENIC consensus statement on surveillance and management of dysplasia in inflammatory bowel disease: praise and words of caution. Gastroenterology. 2015;148(3):462–7.  https://doi.org/10.1053/j.gastro.2015.01.029.CrossRefPubMedGoogle Scholar
  58. 58.
    Goldstone R, Itzkowitz S, Harpaz N, et al. Progression of low-grade dysplasia in ulcerative colitis: effect of colonic location. Gastrointest Endosc. 2011;74:1087–93.CrossRefPubMedGoogle Scholar
  59. 59.
    Venkatesh PG, Jegadeesan R, Gutierrez NG, et al. Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis. J Crohns Colitis. 2013;7:968–73.CrossRefPubMedGoogle Scholar
  60. 60.
    Pekow JR, Hetzel JT, Rothe JA, Hanauer SB, Turner JR, Hart J, et al. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010;16(8):1352–6.  https://doi.org/10.1002/ibd.21184.PubMedCentralCrossRefPubMedGoogle Scholar
  61. 61.
    Marion JF, Waye JD, Israel Y, Present DH, Suprun M, Bodian C, et al. Chromoendoscopy is more effective than standard colonoscopy in detecting dysplasia during long-term surveillance of patients with colitis. Clin Gastroenterol Hepatol. 2016;14(5):713–9.  https://doi.org/10.1016/j.cgh.2015.11.011.CrossRefPubMedGoogle Scholar
  62. 62.
    Gasia MF, Ghosh S, Panaccione R, Ferraz JG, Kaplan GG, Leung Y, et al. Targeted biopsies identify larger proportions of patients with colonic neoplasia undergoing high-definition colonoscopy, dye chromoendoscopy, or electronic virtual chromoendoscopy. Clin Gastroenterol Hepatol. 2016;14(5):704–12 e4.  https://doi.org/10.1016/j.cgh.2015.12.047.CrossRefPubMedGoogle Scholar
  63. 63.
    Deepak P, Hanson GJ, Fletcher JG, Tremaine WJ, Pardi DS, Kisiel JB, et al. Incremental diagnostic yield of chromoendoscopy and outcomes in inflammatory bowel disease patients with a history of colorectal dysplasia on white-light endoscopy. Gastrointest Endosc. 2016;83(5):1005–12.  https://doi.org/10.1016/j.gie.2015.09.021.CrossRefPubMedGoogle Scholar
  64. 64.
    Krugliak Cleveland N, Colman RJ, Rodriquez D, Hirsch A, Cohen RD, Hanauer SB, et al. Surveillance of IBD using high definition colonoscopes does not miss adenocarcinoma in patients with low-grade dysplasia. Inflamm Bowel Dis. 2016;22(3):631–7.  https://doi.org/10.1097/MIB.0000000000000634.CrossRefPubMedGoogle Scholar
  65. 65.
    Mooiweer E, van der Meulen-de Jong AE, Ponsioen CY, et al. Chromoendoscopy for surveillance in inflammatory bowel disease does not increase neoplasia detection compared with conventional colonoscopy with random biopsies: results from a large retrospective study. Am J Gastroenterol. 2015;110(7):1014–21.  https://doi.org/10.1038/ajg.2015.63.CrossRefPubMedGoogle Scholar
  66. 66.
    Fumery M, Dulai PS, Gupta S, Prokop LJ, Ramamoorthy S, Sandborn WJ, et al. Incidence, risk factors, and outcomes of colorectal cancer in patients with ulcerative colitis with low-grade dysplasia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(5):665–74 e5.  https://doi.org/10.1016/j.cgh.2016.11.025.CrossRefPubMedGoogle Scholar
  67. 67.
    Marion JF, Waye JD, Present DH, Israel Y, Bodian C, Harpaz N, et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol. 2008;103(9):2342–9.  https://doi.org/10.1111/j.1572-0241.2008.01934.x.CrossRefPubMedGoogle Scholar
  68. 68.
    Kaltenbach T, McQuaid KR, Soetikno R, Laine L. Improving detection of colorectal dysplasia in inflammatory bowel disease surveillance. Gastrointest Endosc. 2016;83(5):1013–4.  https://doi.org/10.1016/j.gie.2015.11.003.CrossRefPubMedGoogle Scholar
  69. 69.
    Carballal S, Maisterra S, Lopez-Serrano A, et al. Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD. Gut. 2016;Google Scholar
  70. 70.
    Picco MF, Pasha S, Leighton JA, Bruining D, Loftus EV Jr, Thomas CS, et al. Procedure time and the determination of polypoid abnormalities with experience: implementation of a chromoendoscopy program for surveillance colonoscopy for ulcerative colitis. Inflamm Bowel Dis. 2013;19(9):1913–20.  https://doi.org/10.1097/MIB.0b013e3182902aba.PubMedGoogle Scholar
  71. 71.
    Davies J, Burke D, Olliver JR, et al. Methylene blue but not indigo carmine causes DNA damage to colonocytes in vitro and in vivo at concentrations used in clinical chromoendoscopy. Gut. 2007;56:155–6.PubMedCentralCrossRefPubMedGoogle Scholar
  72. 72.
    Repici A, Di Stefano AF, Radicioni MM, et al. Methylene blue MMX tablets for chromoendoscopy. Safety tolerability and bioavailability in healthy volunteers. Contemp Clin Trials. 2012;33(2):260–7.  https://doi.org/10.1016/j.cct.2011.11.006.CrossRefPubMedGoogle Scholar
  73. 73.
    Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson d, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143(3):844–57.  https://doi.org/10.1053/j.gastro.2012.06.001.CrossRefPubMedGoogle Scholar
  74. 74.
    Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology. 1999;117(6):1288–94; discussion 1488-91.  https://doi.org/10.1016/S0016-5085(99)70278-7.CrossRefPubMedGoogle Scholar
  75. 75.
    Odze RD, Farraye FA, Hecht JL, Hornick JL. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol. 2004;2(7):534–41.  https://doi.org/10.1016/S1542-3565(04)00237-X.CrossRefPubMedGoogle Scholar
  76. 76.
    Rubin PH, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology. 1999;117:1295–300.CrossRefPubMedGoogle Scholar
  77. 77.
    Vieth M, Behrens H, Stolte M. Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment. Gut. 2006;55:1151–5.PubMedCentralCrossRefPubMedGoogle Scholar
  78. 78.
    Wanders LK, Dekker E, Pullens B, et al. Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2014;12:756–64.CrossRefPubMedGoogle Scholar
  79. 79.
    Ten Hove JR, Mooiweer E, Dekker E, et al. Low rate of dysplasia detection in mucosa surrounding dysplastic lesions in patients undergoing surveillance for inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2017;15(2):222–8 e2.  https://doi.org/10.1016/j.cgh.2016.08.035.CrossRefPubMedGoogle Scholar
  80. 80.
    Smith LA, Baraza W, Tiffin N, et al. Endoscopic resection of adenoma-like mass in chronic ulcerative colitis using a combined endoscopic mucosal resection and cap assisted submucosal dissection technique. Inflamm Bowel Dis. 2008;14:1380–6.CrossRefPubMedGoogle Scholar
  81. 81.
    Blonski W, Kundu R, Furth EF, et al. High-grade dysplastic adenoma-like mass lesions are not an indication for colectomy in patients with ulcerative colitis. Scand J Gastroenterol. 2008;43:817–20.CrossRefPubMedGoogle Scholar
  82. 82.
    Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003;125:1311–9.CrossRefPubMedGoogle Scholar
  83. 83.
    Thomas T, Abrams KA, Robinson RJ, et al. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther. 2007;25(6):657–68.  https://doi.org/10.1111/j.1365-2036.2007.03241.x.CrossRefPubMedGoogle Scholar
  84. 84.
    Befrits R, Ljung T, Jaramillo E, et al. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon rectum. 2002;45:615–20.Google Scholar
  85. 85.
    Hata K, Watanabe T, Kazama S, et al. Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23-year surveillance programme in the Japanese population. Br J Cancer. 2003;89:1232–6.PubMedCentralCrossRefPubMedGoogle Scholar
  86. 86.
    Lim CH, Dixon MF, Vail A, Forman D, Lynch d, Axon AT. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut. 2003;52(8):1127–32.  https://doi.org/10.1136/gut.52.8.1127.PubMedCentralCrossRefPubMedGoogle Scholar
  87. 87.
    Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91(4):854–62.  https://doi.org/10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z.CrossRefPubMedGoogle Scholar
  88. 88.
    Dekker E, van den Broek FJ, Reitsma JB, et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy. 2007;39(3):216–21.  https://doi.org/10.1055/s-2007-966214.CrossRefPubMedGoogle Scholar
  89. 89.
    Ignjatovic A, East JE, Subramanian V, Suzuki N, Guenther T, Palmer N, et al. Narrow band imaging for detection of dysplasia in colitis: a randomized controlled trial. Am J Gastroenterol. 2012;107(6):885–90.  https://doi.org/10.1038/ajg.2012.67.CrossRefPubMedGoogle Scholar
  90. 90.
    van den Broek FJ, Fockens P, van Eeden S, et al. Narrow-band imaging versus high-definition endoscopy for the diagnosis of neoplasia in ulcerative colitis. Endoscopy. 2011;43(02):108–15.  https://doi.org/10.1055/s-0030-1255956.CrossRefPubMedGoogle Scholar
  91. 91.
    Pellise M, Lopez-Ceron M, Rodriguez de Miguel C, et al. Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. Gastrointest Endosc. 2011;74:840–8.CrossRefPubMedGoogle Scholar
  92. 92.
    Leifeld L, Rogler G, Stallmach A, Schmidt C, Zuber-Jerger I, Hartmann F, et al. White-light or narrow-band imaging colonoscopy in surveillance of ulcerative colitis: a prospective multicenter study. Clin Gastroenterol Hepatol. 2015;13(10):1776–81 e1.  https://doi.org/10.1016/j.cgh.2015.04.172.CrossRefPubMedGoogle Scholar
  93. 93.
    Neumann H, Kiesslich R. Endomicroscopy and endocytoscopy in IBD. Gastrointest Endosc Clin N Am. 2013;23(3):695–705.  https://doi.org/10.1016/j.giec.2013.03.006.CrossRefPubMedGoogle Scholar
  94. 94.
    Gunther U, Kusch D, Heller F, et al. Surveillance colonoscopy in patients with inflammatory bowel disease: comparison of random biopsy vs. targeted biopsy protocols. Int J Color Dis. 2011;26:667–72.CrossRefGoogle Scholar
  95. 95.
    Hlavaty T, Huorka M, Koller T, et al. Colorectal cancer screening in patients with ulcerative and Crohn’s colitis with use of colonoscopy, chromoendoscopy and confocal endomicroscopy. Eur J Gastroenterol Hepatol. 2011;23:680–9.CrossRefPubMedGoogle Scholar
  96. 96.
    Rispo A, Castiglione F, Staibano S, et al. Diagnostic accuracy of confocal laser endomicroscopy in diagnosing dysplasia in patients affected by long-standing ulcerative colitis. World J Gastrointest Endosc. 2012;4:414–20.PubMedCentralCrossRefPubMedGoogle Scholar
  97. 97.
    Naymagon S, Marion JF. Surveillance in inflammatory bowel disease: chromoendoscopy and digital mucosal enhancement. Gastrointest Endosc Clin N Am. 2013;23:679–94.CrossRefPubMedGoogle Scholar
  98. 98.
    Subramanian V, Ragunath K. Advanced endoscopic imaging: a review of commercially available technologies. Clin Gastroenterol Hepatol. 2014;12(3):368–76 e1.  https://doi.org/10.1016/j.cgh.2013.06.015.CrossRefPubMedGoogle Scholar
  99. 99.
    Committee AT. Confocal laser endomicroscopy. Gastrointest Endosc. 2014;80:928–38.CrossRefGoogle Scholar
  100. 100.
    Committee AT, Kwon RS, Wong Kee Song LM, et al. Endocytoscopy. Gastrointest Endosc. 2009;70(4):610–3.  https://doi.org/10.1016/j.gie.2009.06.030.CrossRefGoogle Scholar
  101. 101.
    Kisiel JB, Yab TC, Nazer Hussain FT, Taylor WR, Garrity-Park MM, Sandborn WJ, et al. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37(5):546–54.  https://doi.org/10.1111/apt.12218.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pennine Acute Hospitals NHS Trust, Section of Inflammatory Bowel Diseases, Department of Gastroenterology, Institute of Inflammation and Repair, Manchester Academic Health SciencesUniversity of ManchesterManchesterUK
  2. 2.Section of Gastroenterology, Boston Medical CenterBoston University School of MedicineBostonUSA

Personalised recommendations